Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.59 |
| ▸ | TSHR | P16473 | 1/20 | 0.59 |
| ▸ | RECQL | P46063 | 1/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.55 |
| ▸ | POLB | P06746 | 2/20 | 0.55 |
| ▸ | LMNA | P02545 | 4/20 | 0.52 |
| ▸ | HPGD | P15428 | 1/20 | 0.51 |
| ▸ | PKM | P14618 | 1/20 | 0.50 |
| ▸ | HTT | P42858 | 3/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12706351 | 0.81 | ALDH1A1 (0.56) | SMN1; SMN2TSHRALDH1A1LMNAHPGD | |
| SCHEMBL11158442 | 0.81 | TSHR (0.65) | SMN1; SMN2TSHRRECQLALDH1A1POLB | |
| SCHEMBL28309465 | 0.81 | RECQL (0.65) | SMN1; SMN2TSHRRECQLALDH1A1POLB | |
| SCHEMBL2077746 | 0.80 | TSHR (0.65) | SMN1; SMN2TSHRRECQLALDH1A1POLB | |
| SCHEMBL13821653 | 0.80 | TSHR (0.60) | SMN1; SMN2TSHRRECQLALDH1A1POLB | |
| SCHEMBL2950454 | 0.79 | SMN1; SMN2 (0.63) | SMN1; SMN2TSHRRECQLALDH1A1POLB | |
| SCHEMBL2950453 | 0.79 | SMN1; SMN2 (0.63) | SMN1; SMN2TSHRRECQLALDH1A1POLB | |
| SCHEMBL12706463 | 0.79 | HTT (0.56) | SMN1; SMN2TSHRALDH1A1POLBLMNA | |
| SCHEMBL14590513 | 0.79 | SMN1; SMN2 (0.64) | SMN1; SMN2TSHRRECQLALDH1A1POLB | |
| SCHEMBL12706339 | 0.78 | MEN1 (0.61) | SMN1; SMN2TSHRRECQLALDH1A1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7919517-B2 | Indazole derivatives | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2011-04-05 | — | — | US | disclosed |
| US-20090082348-A1 | INDAZOLE DERIVATIVES | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2009-03-26 | — | — | US | disclosed |
| US-7470717-B2 | Indazole derivatives | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2008-12-30 | — | — | US | disclosed |
| US-20070117856-A1 | Indazole derivatives | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2007-05-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070117856-A1 | Indazole derivatives | IGF1R, NR0B2, ADRA2B | SMN1; SMN2 4219/4885TSHR 127/4885RECQL 3420/4885 |
| US-20090082348-A1 | INDAZOLE DERIVATIVES | IGF1R, NR0B2, ADRA2B | SMN1; SMN2 4219/4885TSHR 127/4885RECQL 3420/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.